Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evogliptin for inhibition of aortic valve calcification progression in type 2 diabetes mellitus with mild-to-moderate aortic stenosis
KCT0005375Phase 4Terminated
- Sponsor
- Asan Medical Center
- Start
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of DA5221-B2 in type 2 diabetes mellitus (T2DM), aortic stenosis (AS), aortic valve calcification (CAVD), sponsored by Asan Medical Center. Started Nov 2020; status: terminated.
02
Drugs
DA5221-B2
03
Conditions
type 2 diabetes mellitus (T2DM)aortic stenosis (AS)aortic valve calcification (CAVD)
Beyond the preview
Go deeper on KCT0005375.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0005375.